跳至主要内容
临床试验/NCT00096798
NCT00096798已完成3 期

A Double-Blind, Placebo-Controlled Study of Ethyl Eicosapentanoic Acid (Ethyl-EPA) in Major Depressive Disorder

National Center for Complementary and Integrative Health (NCCIH)2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2001年9月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
80
试验地点
2
主要终点
Alleviation of depressive symptoms

研究概览

简要总结

The purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-EPA), an omega-3 fatty acid, in treating depression.

详细描述

Evidence suggests that omega-3 fatty acids may help reduce symptoms of depression. This study will determine whether ethyl-EPA, an omega-3 fatty acid, can be used safely and effectively to treat major depression.

Participants will be randomly assigned to receive either ethyl EPA-containing pills or placebo daily for 8 weeks. Each week, participants will be asked to complete questionnaires which will be used to assess the severity of their depression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Major depressive disorder

排除标准

  • Serious comorbid psychiatric disorder
  • Unstable medical illness
  • Prior use of any omega-3 fatty acid product

结局指标

主要结局

Alleviation of depressive symptoms

次要结局

未报告次要终点

研究者

研究点 (2)

Loading locations...

相似试验